Autopsy report · NCT06765954

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

“Study was redeveloped into a new protocol”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

ImmunityBio, Inc.

Sponsor type

Industry

Conditions

High-risk Prostate Cancer

Interventions

N-803 (IL-15 Superagonist); ETBX-071 (PSA-based Oncolytic Virus); M-CENK (Activated NK Cells); External Beam Radiation Therapy (EBRT); Androgen Deprivation Therapy (ADT); Post-radiation immunotherapy

Participants

0

Trials that died the same way

• Study of Stored Tumor Samples in Young Patients With Brain Tumors
  “New Protocol that replaces the current study” (91% match in meaning)
• Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients
  “study will be started under a new modified protocol” (87% match in meaning)
• Effects of Whole Food, Plant-Based Nutrition on Chronic Kidney Disease With Proteinuria
  “Substantially redesigning study protocol and opening a new study in the future.” (80% match in meaning)
• Estimate Serum Oxytocin PD Range in the Periphery
  “Study will be replaced by a revised study protocol” (79% match in meaning)
• Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance Glasses
  “The study protocol needed to be modified” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.